AMPK Signaling Pathway

AMPK Signaling Pathway

Publication date: Mar 10, 2020

AMPK positively regulates catabolic pathways such as fatty acid oxidation and autophagy when the concentration of intracellular ATP is low, while it negatively affects anabolic pathways such as glycogen synthesis, de novo synthesis of triglycerides, fatty acids, and cholesterol.

A number of such naturally occurring compounds are attracting the attention of researchers in preventing diseases through activation of AMPK.

For instance, a study carried out on rodent models for Alzheimer’s disease and Huntington’s disease, demonstrated that administration of resveratrol, a sirtuin 1 activator, reduced neurodegeneration that can be partially attributed to AMPK activation.

The therapeutic effects of resveratrol were attributed to activation of AMPK through autophagy, antioxidant gene expression, and mitochondrial biogenesis.

AMPK activation in cancer therapy: To enhance the efficacy of combination drugs used in cancer treatment, and to prevent multidrug resistance, a number of studies have been looking at using AMPK regulators for targeted therapy.

Although the molecular mechanism is yet to be understood with certainty, metformin positively influences activation of AMPK and can be investigated further in cancer prevention and treatment.

Although AMPK activation is being researched extensively for cancer therapy, activation of AMPK can sometimes promote the proliferation of cancer cells.

In prostate cancer cases, AMPK activation will cause elevation of Ca2+/CaM-dependent protein kinase kinase β (CaMKKβ) expression thereby causing further proliferation of prostate cancer cells.

This shows the complexity involved in cancer therapy using AMPK activation where tumor suppression would depend on the type of pathway and cancer cells involved.

A number of substrates of AMPK are now known to be involved in maintaining activities such as growth, metabolism, autophagy, and cell polarity.

What remains a challenge, and needs to be investigated further, are targets that bring about therapeutic effects upon activation of AMPK in neurodegenerative disorders, metabolic disorders, and cancer.

Concepts Keywords
Adenosine Diphosphate FGF21
Adenosine Monophosphate Radiation
Adenosine Triphosphate AMP-activated protein kinase
ADP Metformin
Aging Autophagy
Amino Acids STK11
AMP Adenosine monophosphate
AMPK MTORC1
Anabolic Branches of biology
Antioxidant Nucleotides
ATP Radiation therapy
Autophagy NSCLC
Benzimidazole Inflammation
Calcium Due infection injury
Calmodulin Potential treat diseases
Cancer Diseases
Cap Tumors
Carcinoma Cancer
Catabolic Translation energy stress
Catalytic Tumor
Chemotherapeutic Agents
Cholesterol
Coactivator
Colorectal Cancer
Combination Drugs
Conformational Change
CREB
Curcumin
Cyclooxygenase 2
Cytokines
Diabetes
Dopaminergic
Energy
Energy Homeostasis
Epidemiological
Eukaryotes
FAO
Fatty Acid
Fatty Acids
FOXO
Free Fatty Acids
Gluconeogenesis
Gluconeogenic
Glucose
Glycogen
Heat Shock
Hepatocyte
Histone
Homolog
Hyperglycemic
Infection
Inflammation
Interact
Intracellular
Ischemia
Kinase
Lipid Metabolism
Lipolysis
Liver
Lung
Macrophages
Metformin
MTORC1
Multidrug Resistance
Natural Products
Neurodegeneration
Neurodegenerative Diseases
Neurons
Neutrophils
NSAIDs
Nutrition
Obesity
Oxidation
Oxidative Stress
Phosphatase
Phosphatases
Phosphoenolpyruvate Carboxykinase
Phosphorylation
Quercetin
Radiation Therapy
Rapamycin
Resveratrol
Rodent
Salicylates
Sirtuin
Stress
T Cells
Targeted Therapy
Threonine
TNF
Toxicity
Transcription
Transcription Factor
Transcription Factors
Triglycerides
Tumor
Tumor Necrosis Factor
Tumor Suppressor Gene

Semantics

Type Source Name
disease MESH aging
drug DRUGBANK Amino acids
disease MESH lifestyle
disease MESH inflammation
disease MESH Obesity
disease MESH oxidative stress
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Adenosine
drug DRUGBANK Metformin
drug DRUGBANK Troglitazone
drug DRUGBANK Curcumin
drug DRUGBANK Quercetin
disease MESH type 2 diabetes
drug DRUGBANK Resveratrol
drug DRUGBANK Benzimidazole
disease MESH neurodegenerative diseases
drug DRUGBANK Phosphoenolpyruvate
drug DRUGBANK Cholesterol
pathway KEGG Autophagy
drug DRUGBANK Calcium
disease MESH tumors
drug DRUGBANK L-Threonine
disease MESH ischemia
disease MESH shock
drug DRUGBANK ATP
disease MESH growth
pathway KEGG AMPK signaling pathway
drug DRUGBANK Adenosine phosphate
disease MESH small cell lung carcinoma
disease MESH colorectal cancer
pathway KEGG Colorectal cancer
disease MESH infection
drug DRUGBANK Epigallocatechin
disease MESH prostate cancer
pathway KEGG Prostate cancer

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *